Lesley Russell
CIK 1374636 · Chief Medical Officer · last filed 2026-03-13
Lesley Russell is a Chief Medical Officer who has filed 56 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for ENTA, was dated Mar 13, 2026. Across all open-market trades the lifetime net is −$4.7M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
5
56
-$4.68M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ENTA | Director | — | $11.90 | — | $0 | 11 | 2026-03-13 |
| ENDOCYTE INC (ECYT) Delisted | Director | 0 | — | — | $0 | 8 | 2018-12-21 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Director | 24,913 | — | — | $0 | 10 | 2018-06-08 |
| TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | Chief Operating Officer | 20,000 | — | — | $98.0K | 3 | 2015-01-30 |
| CEPHALON INC (CEPH) Delisted | Exec VP, Chief Medical Off | 0 | — | — | -$4.78M | 23 | 2011-10-17 |
Recent Filings
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-13 | ENTA | Grant (A) | — | $0 | EDGAR |
| 2025-03-14 | ENTA | Grant (A) | — | $0 | EDGAR |
| 2024-03-08 | ENTA | Grant (A) | — | $0 | EDGAR |
| 2023-03-06 | ENTA | Grant (A) | — | $0 | EDGAR |
| 2022-03-07 | ENTA | Grant (A) | — | $0 | EDGAR |
| 2021-03-04 | ENTA | Grant (A) | — | $0 | EDGAR |
| 2020-02-28 | ENTA | Grant (A) | — | $0 | EDGAR |
| 2019-03-01 | ENTA | Grant (A) | — | $0 | EDGAR |
| 2018-12-21 | ENDOCYTE INC (ECYT) Delisted | Disp (D) | −11,100 | -$266.4K | EDGAR |
| 2018-06-08 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Grant (A) | +3,578 | $0 | EDGAR |